There is a chronic shortage of organs available for transplant. Bioprinted organs could dramatically increase accessibility to all patients in need of transplants. Some simpler biofabricated tissues are already entering the clinic, with the promise of more complicated 3D bioprinted organs undergoing clinical trials by the middle of the next decade. Scalable, efficient and economic manufacturing solutions for key raw materials, such as recombinant protein bioinks, growth factors and maturogens, will be essential for successful commercialization.
Post-translational modification is a critical step in the synthesis of biotherapeutic molecules. Among these alterations to the original naked protein, glycosylation may be the most significant and difficult to properly complete. In this roundtable, we discuss the challenges and the pitfalls involved in generating authentic glycosylated molecules in cell culture and microbial production facilities. GEN interviewed several authorities in the field of protein production.
iBio has expanded its CDMO service offerings to include independent sterile liquid cGMP fill-finish services to support the preclinical and clinical trial needs of drug developers. This new service complements iBio’s existing biologics bulk drug …
iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from early development through fill and finish for research-grade, …
Mammalian cell culture is widely used for biologic drug substance production, but the high cost and long development times pose challenges to the implementation of this technology in many parts of the world. Traditional protein expression systems are …